guest column

Houston apartment company on 6 smart home technologies for renters

Optimize you home with these smart technologies. Photo courtesy of Caydon

With recent changes to the ways we work and live, the importance of smart home technology in apartment complexes is becoming more important than ever. Residents not only want to streamline their lifestyles, but are looking for ways to limit contact when performing interactions.

A great example of smart home technology can be found at Drewery Place in Midtown. Built by Australian property developer Caydon, Drewery Place is at the forefront of smart home technology, providing residents with plenty of options to simplify their lifestyles in contactless style. Below are just some of the smart home features that residents in this tech savvy development enjoy.

Latch keyless entry

Fumbling for your keys is a thing of the past. Now you can use your phone to open not only your apartment door, but also resident-only areas such as the fitness center, pool area and pet park.

Smart thermostats

Come home to the perfect climate with smart thermostat technology. Now you can flick on the heat or blast in the cool as you can control the temperature from anywhere on your phone.

Set the scene

You know those days when things are just a little too bright? Or maybe you want to lighten the mood a little? Whatever you're feeling, get your lighting to match it with dimmer and lighting controls on your phone. There's also a host of pre-programmed lighting scenes so you can set the mood for any occasion.

Alexa — your new best friend

All of Drewery Place's apartments are wired and ready for Amazon's smart assistant, Alexa. Using voice control, you can get Alexa to adjust lighting, play your favorite music, summon an Uber and even order Amazon packages.

Caydon HQ

All residents at Drewery Place can pay their rent, request a maintenance repair, book amenities, organize a dog walker or request a Spruce chore such as a deep clean for their apartment. You can also get notifications from the concierge on when packages arrive and arrange contactless pickup from the downstairs mail lockers.

Get physical

Not into group classes? Organize a training session for one, anytime at the fitness center using MIRROR gym technology. This is literally a magic mirror, where a virtual trainer will train with you in the class of your choice. There's over 20+ categories to choose from, plus they'll correct your form in real-time — so you get personalized attention minus the class numbers.

The staff at Drewery Place are also taking extra precautions to help stop the spread of COVID-19 with regular deep cleanings, social distancing protocol and signage throughout the building. If you want to learn more, you can organize a personal tour complete with masks and social distancing.

------

Emma Alexander is acting chief of operations and director of sales and marketing for Caydon.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted